| Price | 14.78 |
| Price Change Today | -$0.49 (-3.21%) |
| P&P rating | ![]() |
| Zacks Rank | 3 - HOLD |
| Open Price | $15.20 |
| Previous Close | $15.27 |
| Daily Range | $14.61 - $15.38 |
| 52-Week Range | $6.46 - $43.96 |
| Volume | 9,520,277 |
| Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases. | |




Very bad marketing and i believe the strategy has changed we shall soon here about, that would lift pps to 15$ at first, then 20$ in 4-6 months.
My Target is 20$ in the short term.
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Originally, my order was scheduled to go in @ $5, but (my luck) DNDN stopped trading for almost 3 hours, due to 'trader irregularities!' The original order did not go through. Had the stock tanked, no doubt it would have gone through.
I again picked up DNDN at $28. At $25, DNDN seemed to receive increased daily volume and options action. Now that it has moved past $30 and has held there, I believe the guy who said it would reach $40, either was lucky or really knew, It may take awhile, but if the drug they are producing (a prostate cancer retardant?), receives FDA approval, it will zoom past $60 almost overnight.
I am not a 'WOW' person, but this may be as close as it gets.
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 1 | Comment